Ocata Therapeutics Inc fka OCAT

[Investing123]

http://www.rpbusa.org/rpb/

CEOCAST this weekend:

Advanced Cell Technology (OTCBB: ACTC), a leader in regenerative medicine, announced that the Oregon Health and Science University Institutional Review Board (IRB) has given approval for their center to be a clinical trial site for ACTC’s Phase I/II clinical trial using retinal pigment epithelial cells (RPE) derived from human embryonic stem cells (hESCs) in the treatment of macular degeneration. The Casey Eye Institute (CEI) at Oregon Health and Science University has internal approval to be a part of the prospective, open-label study to determine the safety and tolerability of (RPE) cells following sub-retinal transplantation into patients with Stargardt’s Macular Degeneration (SMD). CEI has successfully collaborated with ACTC’s RPE program since 2007 and will continue this cooperation as a site for this groundbreaking trial of an exciting potential new treatment for SMD. The Casey Eye Institute (CEI) is one of only seven regional eye research centers in the nation sponsored by Research to Prevent Blindness, which is the world’s leading voluntary organization in support of Eye Research. ACTC has also received IRB approval for their Phase I/II trial from the Jules Stein Institute at the University of California, Los Angeles. ACTC stock slipped $0.01 to close last week at $0.20